EEF1A2 and cancer: As one of these first-in-class eEF1A2 degraders, 27 (Figure 5) was shown to degrade eEF1A2 in three cancer cells in a dose-dependent manner, thus holding promise for the treatment of eEF1A2-mediated carcinogenesis.